FDA approves Teva allergy drug
JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.
Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.
"There are some patients with allergic rhinitis who report dissatisfaction with the currently available therapies," Dallas Asthma and Allergy Center allergist Gary Gross said in a statement on behalf of Teva. "The approval of Qnasl offers these patients a safe and effective treatment option with a new dry mode of delivery."
Impax Labs, Tolmar enter collaboration agreement
HAYWARD, Calif., and FORT COLLINS, Colo. — Impax Labs has partnered with a pharmaceutical research, development, manufacturing and commercial operations company on a multiproduct agreement.
Impax Labs and Tolmar will develop, supply and distribute alternative dosage form products. The products and terms of the agreement were not disclosed; however, Impax Labs president and CEO Larry Hsu said the new agreement "represents an ideal extension of [our] initial product agreement."
"In the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base," Hsu said. "Our business development activities will continue to focus on delivering growth from high-value products, technologies and businesses in complementary dosage forms."
Added Tolmar CEO Mike Duncan, "We are very pleased with this agreement. Tolmar is once again recognized as a key player in the specialty pharma space. This agreement is aligned with our long-term corporate strategy and we firmly believe that Impax is the right partner for these products."
McKesson completes Katz Group Canada pharmacy acquisition
SAN FRANCISCO — McKesson on Monday announced that it has completed the previously announced acquisition of the independent banner and franchise businesses of Katz Group Canada in an all-cash transaction that closed March 25.
McKesson in January agreed to acquire the Canadian company’s banner pharmacy business, Drug Trading, and its franchise pharmacy business, Medicine Shoppe Canada, in a deal worth approximately $926 million. Under the terms of the agreement, McKesson substantially will acquire all of the assets of Drug Trading, the shares of Medicine Shoppe Canada and a joint ownership interest in ProPharm’s pharmacy software application.
Katz’s banner and franchise operations will be integrated into McKesson’s Canadian pharmaceutical distribution and services business, which is part of McKesson’s Distribution Solutions segment.
McKesson Canada currently operates a number of banner groups, including Proxim, Associated Retail Pharmacy and Family Health Care Pharmacy.